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Abstract: ATP is an extracellular signal for the immune
system, particularly during an inflammatory response. It is
sensed by the P2X7 receptor, the expression of which is
upregulated by pro-inflammatory cytokines. Activation of
the P2X7 receptor opens a cation-specific channel that
alters the ionic environment of the cell, activating several
pathways, including (i) the inflammasome, leading to
production of IL-1b and IL-18; (ii) the stress-activated
protein kinase pathway, resulting in apoptosis; (iii) the
mitogen-activated protein kinase pathway, leading to
generation of reactive oxygen and nitrogen intermedi-
ates; and (iv) phospholipase D, stimulating phagosome-
lysosome fusion. The P2X7 receptor can initiate host
mechanisms to remove pathogens, most particularly
those that parasitise macrophages. At the same time,
the P2X7 receptor may be subverted by pathogens to
modulate host responses. Moreover, recent genetic
studies have demonstrated significant associations be-
tween susceptibility or resistance to parasites and
bacteria, and loss-of-function or gain-of-function poly-
morphisms in the P2X7 receptor, underscoring its
importance in infectious disease.
Introduction
In addition to its role in cellular metabolism, the purine
nucleotide ATP acts as an important extracellular messenger in a
range of physiological processes, including synaptic transmissions,
taste, bone formation/resorption, male fertility, blood pressure
regulation, and inflammation [1–3]. Its effects are mediated
through activation of purinergic receptors such as the P1
adenosine and the P2 nucleotide receptors [4]. Purinergic
receptors are found on all types of cells in mammalian tissues,
with many cells expressing multiple P1 and P2 subtypes [5].
P2 receptors are classified into two subfamilies—the P2X
ligand-gated ion channels and the P2Y G protein–coupled
receptors [4]. To date, seven P2X subunits (P2X1–P2X7) and
eight P2Y subunits (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12,
P2Y13, P2Y14) have been identified [5]. P2X receptors are fast
acting and open a cation-selective channel within milliseconds of
ATP binding, whereas P2Y receptors are slower acting because
their activation proceeds through second-messenger pathways, in
the form of G proteins. Most P2X receptors have a low affinity for
ATP, usually within the mM–mM range, while P2Y receptors are
responsive to nM concentrations of ATP [6].
The P2X Family
There are seven mammalian P2X subunits that assemble as
homo- or heterotrimers to form functional receptors [7]. Each
subunit consists of intracellular N and C termini and two
membrane-spanning segments, separated by an extracellular loop
containing ten conserved cysteine residues, thought to form
disulfide bonds, and lysine and phenylalanine residues involved
in activation by ATP [7]. The C termini of the various P2X
subunits vary in length from 25 amino acids in the P2X6 receptor
to 240 amino acids in the P2X7 receptor and are associated with
the functional properties specific to each receptor [2,8]. Each
subunit is able to bind a molecule of ATP although the sensitivity
to ATP binding varies widely within the family, with the P2X1
receptor requiring nM levels for activation, whereas the P2X7
receptor requires mM concentrations [3]. Brief exposure of all
P2X receptors to ATP opens up a channel that renders the cell
permeable to Na
+,K
+, and Ca
2+, causing an increase in
intracellular Ca
2+ and Na
+ concentrations and a decrease in
intracellular K
+. This leads to depolarisation of the cell membrane
and initiation of downstream Ca
2+ signalling pathways [3].
Prolonged exposure of the P2X1 and P2X3 receptors to ATP
results in desensitisation and closure of the pore; however,
prolonged exposure of the P2X2, P2X4, P2X5, and P2X7 receptors
to ATP results in sustained membrane depolarisation and the
opening of large transmembrane pores [2] that are permeable to
hydrophilic molecules between 314 Da and 900 Da, depending on
the cell type studied [9,10].
The P2X7 Receptor
The P2X7 receptor is highly expressed by cells of the
haemopoietic lineage and can mediate cell death, killing of
infectious organisms, and regulation of the inflammatory response
[7,11,12]. The receptor is constitutively expressed. Under normal
physiological conditions, activity of the receptor is kept at a low
level by the extracellular concentration of divalent cations such as
Ca
2+ and Mg
2+, which appear to alter the affinity of ATP binding
in an allosteric manner, and this is believed to prevent unnecessary
Citation: Miller CM, Boulter NR, Fuller SJ, Zakrzewski AM, Lees MP, et al. (2011) The
Role of the P2X7 Receptor in Infectious Diseases. PLoS Pathog 7(11): e1002212.
doi:10.1371/journal.ppat.1002212
Editor: Marianne Manchester, University of California San Diego, United States of
America
Published November 10, 2011
Copyright:  2011 Miller et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: Professors Smith and Wiley gratefully acknowledge the support of the
Australian Research Council (ARC) for funding through its Discovery Project
Scheme (DP0666515). The ARC played no role in the literature review, writing,
editing or decision to publish this manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: nicholas.smith@jcu.edu.au
PLoS Pathogens | www.plospathogens.org 1 November 2011 | Volume 7 | Issue 11 | e1002212cell permeability and pore formation [7,13]. Under pathophysi-
ological conditions, for example at sites of inflammation or
infection, expression is up-regulated by inflammatory cytokines
[14]. Extracellular concentrations of Ca
2+ and Mg
2+ decrease as a
consequence of dead and damaged cells releasing their cytosolic
contents. This ‘‘dilution’’, combined with an increase in ATP (also
released from lysing cells), enhances P2X7 receptor activation
[7,13].
The alteration in the ionic environment of the cell, resulting
from P2X7 receptor activation, triggers a number of cellular
pathways, depending on cell type (Figure 1), including: (i) the
inflammasome, leading to production of IL-1b and IL-18 [15–17];
(ii) the stress-activated protein kinase pathway, resulting in
apoptosis [18]; (iii) the mitogen-activated protein kinase pathway,
leading to generation of reactive oxygen and nitrogen intermedi-
ates [11,19–21]; and (iv) phospholipase D, stimulating phago-
some–lysosome fusion [22]. The involvement of the P2X7 receptor
in these pathways suggests that it functions as a major regulator of
inflammation. Indeed, absence of the P2X7 receptor alters
immune cell function with the effect seen dependent on context.
For example, in a murine model of arthritis, P2X7 receptor–
deficient animals showed a reduction in the incidence and severity
of the disease compared with wild-type animals [23]; however, in a
study of autoimmune encephalomyelitis, P2X7 receptor–deficient
animals had exacerbated neuroinflammation compared with wild-
type animals [24]. Moreover, a number of change-of-function
polymorphisms, most of which render the receptor inactive or with
reduced function, have also been noted in the human population
(Table 1) [25–32], and genetic association studies have uncovered
links between some of these polymorphisms and resistance/
susceptibility to mood disorders, bone diseases, and, most
particularly, infectious disease [26]. It should be noted, however,
that immune cells also express P2Y receptors, such as P2Y2, which
are also activated by inflammatory cytokines and, so, may also
contribute to the regulation of inflammation [5].
The P2X7 Receptor and Intracellular Bacteria
Mycobacteria, such as Mycobacterium tuberculosis, the causative
agent of human tuberculosis, are able to survive and replicate in
phagosomes within macrophages by inhibiting phagosomal fusion
with lysosomes [33]. Treatment of infected macrophages with
ATP, however, can overcome the phagosome–lysosome fusion
block, leading to the killing of intracellular bacilli [34]. The process
appears to be mediated by P2X7 receptors; bactericidal activity is
markedly reduced in P2X7 receptor–deficient macrophages [34].
It involves activation of phospholipase D; thus, phospholipase D
blockers inhibit killing of intracellular mycobacteria following ATP
treatment [34]. Blocking macrophage phospholipase D activity,
however, does not inhibit macrophage apoptotic death, demon-
strating that, while ATP stimulation leads to macrophage
apoptosis and mycobacterial death, these processes can be
uncoupled [34]. More recently, autophagy has been shown to
have a role in the control of mycobacterial infections. ATP
treatment rapidly induces autophagy and mycobacterial killing in
a process dependent on P2X7 receptor activation and Ca
2+ influx
[35].
Evidence for P2X7 receptor involvement in mycobacterial
killing comes from studies showing that loss-of-function polymor-
phisms in the human P2X7 receptor gene lead to increased
susceptibility to M. tuberculosis. Fernando et al. [36] investigated the
prevalence of the 1513 A.C polymorphism in two independent
Southeast Asian cohorts, and found a strong association with the
1513 A.C polymorphism and extrapulmonary tuberculosis.
Subsequent studies have also found that the 1513C allele is a
risk factor in the development of extrapulmonary and pulmonary
tuberculosis in numerous ethnic populations, including Mexican
[37], Russian Slavic [38], and a North Indian Punjabi population
[39]. Recently, an association with the 1513C allele and the
development of extrapulmonary tuberculosis in Turkish children
was also identified [40]. Additional studies have shown associa-
tions between tuberculosis and alleles other than 1513C. Li et al.
[41] studied various P2X7 receptor polymorphisms in a Gambian
population. They found that a protective effect against tuberculosis
was associated with a P2X7 receptor promoter polymorphism at
position 2762, but the 1513 A.C polymorphism discussed above
did not show any significant association. Interestingly, Sambasivan
et al. [42] found an association between development of clinical
tuberculosis and the presence of the 2762C or 1729T allele but
not the 1513C allele in an Indian cohort, while Xiao et al. [43] did
not find an association between either the 1513C allele or the
2762C allele and the development of pulmonary tuberculosis in a
Chinese Han cohort. Overall, though, a recent meta-analysis of
P2X7 receptor gene polymorphism association studies revealed a
strong association between the 1513 A.C polymorphism and
susceptibility to tuberculosis [44].
Data from in vitro studies provide evidence for potential
mechanistic explanations for the association of polymorphisms in
the human P2X7 receptor gene with susceptibility to tuberculosis.
Saunders et al. [45] activated P2X7 receptors on BCG-infected
macrophages from wild-type and homozygous 1513C donors and
showed that P2X7 receptor–activated wild-type macrophages
undergo apoptosis and kill intracellular bacteria; however,
macrophages homozygous for the 1513 A.C loss-of-function
polymorphism fail to undergo apoptosis upon exposure to ATP,
resulting in mycobacterial survival. The effect of other P2X7
receptor polymorphisms was further assessed by Fernando et al.
[46] and Shemon et al. [25], who showed that several P2X7
receptor polymorphisms (946 G.A, 1729 T.A, and 155+1g .t)
result in reduced macrophage apoptosis and mycobacterial killing.
This effect was augmented in compound heterozygous donors
(donors with a heterozygous loss of function polymorphism at
more than one position on the P2X7 receptor gene).
The P2X7 receptor has also been implicated in the innate
response to obligate intracellular bacteria of the Chlamydia genus.
The macrophage is an important reservoir and source of
dissemination of Chlamydia [47,48]. Like mycobacteria, Chlamydia
within macrophages are susceptible to ATP treatment, which
results in the death of ,70%–90% of all intracellular bacteria
[49]. This appears to be the result of P2X7 receptor–dependent
stimulation of phospholipase D activity and subsequent phagolyso-
some fusion. Macrophages from P2X7 receptor gene knockout
mice show no phospholipase D activation after treatment with
ATP and are completely unable to induce ATP-dependent
chlamydial death [50]. Furthermore, inhibiting phospholipase D
activation in normal murine macrophages, by the addition of
butan-1-ol, restores the levels of infection to ,50%, indicating that
phospholipase D is at least partly responsible for chlamydial death
[50]. Moreover, treatment of epithelial cells (the preferred target
cell for chlamydiae) with P2X7 receptor agonists reduces the
infectiveness of the bacteria, again associated with activation of
phospholipase D [51].
Although Chlamydia is clearly vulnerable to P2X7 receptor–
dependent killing, it has developed some resistance to this killing.
Chlamydia-infected J774 murine macrophages are resistant to
apoptosis following treatment with ATP, whereas uninfected cells
undergo apoptosis via P2X7 receptor–dependent pathways [49].
Infection results in markedly reduced activation of the P2X7
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elucidated, but it is known that live, growing organisms are
required [49].
The P2X7 Receptor and Intracellular Parasites
The P2X7 receptor may also play a role in clearance of
intracellular parasites of the Leishmania genus. Murine macrophag-
es and cells cultured from cutaneous lesions of mice infected with
Leishmania amazonensis are more sensitive to P2X7 receptor–
mediated pore formation, inhibiting growth of the intracellular
parasite [52]. Killing of L. amazonensis via the P2X7 receptor is
independent of nitric oxide; instead, it is associated with host cell
apoptosis [52]. However, when P2X7 receptor gene knockout mice
and parental C57BL/6J mice are infected intradermally with
Leishmania major, no difference in resolution of lesions is observed,
suggesting that, in the absence of P2X7 receptors, other anti-
parasitic defence mechanisms compensate to control infection in
vivo (C. Miller, A. Zakrzewski, M. Katrib, N. Smith, unpublished
observations).
Recently, the P2X7 receptor has been implicated in the immune
response to another intracellular protozoan, Toxoplasma gondii,a
parasite that is able to infect and survive in cells of the monocyte/
macrophage lineage. However, the role of the P2X7 receptor in
the response to T. gondii is an intriguing and complex one.
Activation of ‘‘wild-type’’ human or murine macrophages with
ATP induces killing of tachyzoites of both virulent and avirulent
strains of the parasite, but the same treatment of macrophages
Figure 1. Intracellular pathways in immune cells stimulated by P2X7 receptor activation. Activation of the P2X7 receptor with extracellular
ATP opens a cation-specific ion channel that results in the influx of Ca
2+ and Na
+ and the efflux of K
+. Prolonged exposure to ATP creates a pore in the
cell membrane that further increases the intracellular Ca
2+ concentration as well as allowing passage of larger molecules. This alteration in the ionic
environment of the cell triggers a number of cellular pathways. Efflux of K
+ stimulates the formation of the inflammasome, resulting in the activation
of caspase-1. Caspase-1 then cleaves pro-IL-1b and pro-IL-18 to produce IL-1b and IL-18, which are then secreted from the cell as part of the
inflammatory response. The efflux of K
+ and influx of Na
+ also activates the stress-activated protein kinase (SAPK)/c-Jun N-terminal kinases (JNK)
pathway, resulting in the induction of apoptosis. The influx of Ca
2+ activates phospholipase D via RhoA, leading to phagosome/lysosome fusion and
the killing of intracellular pathogens. Influx of Ca
2+ can also activate the mitogen-activated protein kinase p38, stimulating a number of downstream
effects. Phosphorylation of p38 leads to the assembly of NADPH oxidase at the plasma membrane, and the subsequent production of superoxide
(O2
2), enhances nuclear factor kappa B (NFkB) activation via toll-like receptor (TLR) signalling and the subsequent transcription of inducible nitric
oxide synthase (iNOS) and production of nitric oxide (NO), as well as production of tumour necrosis factor (TNF) and IL-6. It can also lead to the
phosphorylation of cAMP response elements binding protein (CREB) via mitogen- and stress-activated kinase 1 (MSK1). Phosphorylated CREB (CREB-
P) sequesters CREB binding protein (CBP), a co-transcription factor required for NFkB-mediated gene transcription, and inhibits transcription of NFkB-
controlled genes. Phosphorylated CREB/CBP also stimulates the production of cAMP-responsive genes such as Cebpb that act to modulate the
inflammatory response through the production of arginase-1 (Arg-1) and IL-10.
doi:10.1371/journal.ppat.1002212.g001
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or macrophages from P2X7 receptor knockout mice has no effect
on parasite viability [53,54]. Interestingly, P2X7 receptor–
mediated killing of T. gondii is not linked to generation of nitric
oxide but is, rather, associated with either phagolysosome
formation accompanied by production of free oxygen radicals
[53] or host cell apoptosis [54]. Thus, P2X7 receptor–mediated
killing of T. gondii has much in common with similarly mediated
killing of Mycobacteria, Chlamydia, and Leishmania.
However, susceptibility to either congenital or ocular toxoplas-
mosis in humans is not associated significantly with the 1513 A.C
loss-of-function polymorphism [55]. Intriguingly, though, resis-
tance to both congenital and ocular toxoplasmosis, in the United
States and Brazil, respectively, is associated positively with the
1068 T.C polymorphism [55]. This polymorphism has recently
been revealed to code for a gain-of-function phenotype in P2X7
receptor activity [27] and may be the true ancestral primate
sequence [55]. Thus, the American and Brazilian association
studies could be interpreted to indicate that reduced inflammatory
disease of the foetus or the eye is a consequence of efficient control
of parasite load in the presence of a fully functional, ancestral
P2X7 receptor [55]. Larger scale association studies may be
needed to truly resolve the association, or otherwise, of various
polymorphisms in the P2X7 receptor and congenital or acquired
toxoplasmosis.
In vivo murine evidence for a significant role of the P2X7
receptor in controlling T. gondii is also inconsistent. In one study,
where mice were infected intraperitoneally with tachyzoites of
the type 2, avirulent ME49 strain of T. gondii, splenic parasite
burdens in different mouse strains were in proportions
consistent with their relative P2X7 receptor activity [54]; thus,
P2X7 receptor knockout mice harboured more parasites than
the parental C57BL/6J mice, whereas, in another study, using
the same parasites and route of infection, no difference in
parasite burden between receptor knockout mice and the
parental strain was observed in vivo [56]. C57BL/6J mice are
known to possess a proline-to-leucine polymorphism at amino
acid 453 in their P2X7 receptor that affects some [22,57–59],
but not all [22,60,61], functions of the receptor and so, C57BL/
6J mice, in turn, had higher parasite burdens than resistant
BALB/c mice with fully functioning P2X7 receptors. It should
be noted, however, that BALB/c and C57BL/6J mice display
differing susceptibilities to T. gondii infection and multiple genes
are associated with this [62]. This may help explain the
discrepancy seen in the in vivo studies.
The apparent inconsistency between P2X7 receptor–mediated
killing of T. gondii in vitro versus in vivo may simply reflect the fact
that type 2 strains of T. gondii, like ME49, induce a wide variety of
pro-inflammatory responses that can control the reproduction of
this parasite [63]. Put another way, P2X7 receptor–mediated
killing is just one means of control of T. gondii, and others remain
operative in knockout mice so that little effect on parasite burden is
observed in vivo. This does, however, indicate that the P2X7
receptor plays a contributory rather than major role in controlling
T. gondii, which is underscored by the fact that production of
several cytokines known to be important in the control of T. gondii,
including gamma-interferon and IL-12, are not inhibited in T.
gondii–infected P2X7 receptor knockout mice [56].
Table 1. Single nucleotide polymorphisms identified in the human P2X7 receptor.
P2X7R Gene
Polymorphism
(Nucleotide Position
and Base Change)
Amino Acid
Change
Location in
Receptor Effect on Receptor Function Disease Association dbSNP ID
151+1g .t Produces null allele Exon1/
intron1 boundary
Loss of function – nonsense-mediated mRNA
decay [25,26]
None known rs35933842
253 T.C Val-76.Ala Extracellular loop Loss of function – partial reduction in pore
formation [27]
None known rs1752809
474 G.A Gly-150.Arg Extracellular loop Loss of function – disrupted protein folding,
no pore formation [27,28]
None known rs28360447
489 C.T His-155.Tyr Extracellular loop Gain of function – enhanced pore formation
and Ca
2+ influx [29]
None known rs208294
835 G.A His-270.Arg Extracellular loop Gain of function – enhanced pore f
ormation [27]
None known rs7958311
853 G.A Arg-276.His Extracellular loop Loss of function – no pore formation [27] None known rs7958316
946 G.A Arg-307.Gln ATP binding site Loss of function – no channel or pore
formation, loss of phospholipase D
activity [30]
None known rs28360457
1068 G.A Ala-348.Thr Cytoplasmic tail Gain of function –enhanced pore
formation and IL-1b secretion [27]
None known rs1718119
1096 C.G Thr-357.Ser Cytoplasmic tail Loss of function – partial reduction in
channel and pore formation [25]
Impaired mycobacterial killing rs2230911
1405 A.G Glu-460.Arg Cytoplasmic tail Loss of function – partial reduction in pore
formation [26,27]
Bipolar disorder, major
depressive disorder
rs2230912
1513 A.C Glu-496.Ala Cytoplasmic tail Loss of function – suboptimal
receptor assembly affecting pore formation
[28,31]
Susceptibility to reactivating
tuberculosis; chronic
lymphocytic leukaemia
rs3751143
1729 T.A Ile-568.Asn Cytoplasmic tail Loss of function – prevention of receptor
trafficking and surface expression [32]
None known rs1653624
doi:10.1371/journal.ppat.1002212.t001
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susceptible to acute toxoplasmosis, losing weight faster and more
dramatically than either C57BL/6J or BALB/c mice [56]. This
susceptibility is not related to relative parasite burdens or a general
alteration in cytokine responses but is associated with an inability
of the knockout mice to limit nitric oxide production [56], a well-
known cause of immunopathology in parasitic infections, including
T. gondii [63]. P2X7 receptor knockout mice infected with T. gondii
also display a delayed—but not abrogated—production of IL-10
[56], which may partially explain their inability to control nitric
oxide production. However, it must be stressed that these
observations are correlative rather than definitive evidence that
the susceptibility to toxoplasmosis apparent in P2X7 receptor–
deficient mice is due to an over-exuberant inflammatory response
and, as this immunoregulatory role for the P2X7 receptor has not
been noted previously, it does require in-depth follow-up.
It is tempting to speculate that extracellular ATP is an effective
danger signal for the immune system, produced as a result of
damage caused by factors like nitric oxide. Since nitric oxide is
potentially so damaging, its production is tightly controlled,
possibly through a negative feedback mechanism. In this scenario,
perhaps cells lacking the P2X7 receptor to sense extracellular ATP
continue producing nitric oxide, whereas cells with functional
receptors are able to regulate nitric oxide production. Figure 1
presents a possible molecular explanation. CREB [64] is a
transcription factor that has been linked to the suppression of
inducible nitric oxide synthase. Extracellular ATP induces
activation of CREB as well as suppressing LPS-induced nitric
oxide production [65]. Although the exact mechanism has not
been elucidated, it is thought that activated CREB sequesters a
transcriptional co-activator, CBP, preventing it from interacting
with the nuclear factor kappa B (NFkB) subunit p65, thus
inhibiting expression of inducible nitric oxide synthase [65].
Hence, during infection with T. gondii, extracellular ATP,
operating through the P2X7 receptor, may activate CREB and
down-regulate nitric oxide production. Cells lacking the P2X7
receptor would, therefore, be less responsive to any build-up in
extracellular ATP. The downstream effect of this would be a lack
of phosphorylation, allowing CBP to remain bound to NFkB, and
inducible nitric oxide synthase transcription and nitric oxide
production to continue indefinitely. Pathology would result.
Conclusion
Clearly, the P2X7 receptor comprises an important part of the
host arsenal against invading pathogens. However, there is
growing evidence of bacteria and parasites subverting the P2X7
receptor pathways for their own advantage, be that through P2X7
receptor–mediated apoptosis, phospholipase D production, or
inhibition of these, as highlighted above.
We speculate that many other pathogens also modulate the host
P2X7 receptor. For example, intracellular parasites of various
genera—including Theileria [66], Leishmania [67,68], Cryptosporidium
[69,70], and Microsporidia [71], and bacteria such as Brucella
[72,73]—all prevent apoptosis of host cells to aid their own
survival. Other pathogens, such as Plasmodium [74,75], Tritricho-
monas [76,77], Streptococcus [78,79], and Legionella [80], actually
increase apoptosis of host cells, thereby reducing the numbers of
circulating immune cells and increasing their chances for survival.
Intriguingly, T. gondii is able to both induce and suppress apoptosis
in a cell type–dependent manner that allows it to establish a
persistent infection [81]. Could some, or all of these, be affecting
host cell apotosis via the P2X7 receptor? Legionella [82], Francisella
[83,84], and Leishmania [85] prevent phagolysosome fusion—
perhaps this is in a P2X7 receptor–dependent manner analogous
to Chlamydia? And, although no definitive link with the P2X7
receptor exists, infection of peritoneal macrophages with Trypano-
soma cruzi down-regulates expression of P2X7 receptors [86], which
may reduce the immune pressure on these parasites. It would be
interesting to investigate whether the P2X7 receptor is a common
target in the immune evasion strategies of these diverse pathogens.
It should also be noted that many of these studies have been
conducted in vitro, and it will be important to confirm that the
P2X7 receptor is playing a non-redundant role in controlling these
pathogens in vivo using P2X7 receptor knockout mice.
Perhaps surprisingly, extracellular pathogens may also be
affected by, or react to, P2X7 receptor activity. For example,
Pseudomonas aeruginosa, a major pathogen in the lungs of cystic
fibrosis patients, and Vibrio cholerae, the causative agent of cholera,
have been shown to secrete multiple enzymes with ATP-modifying
activities, such as adenylate kinase, ATPase, and 59-nucleotidase
[87–89]. It is believed that these enzymes are used to modulate
external ATP levels and, thereby, increase P2X7 receptor function,
mediating apoptosis of macrophages. Extracellular bacteria, such
as Staphylococcus aureus and Escherichia coli, have been linked to P2X7
receptor dependence in a study of caspase-1 activation and
subsequent IL-1b secretion [90]. It is unclear in these studies,
however, how this stimulation of apoptosis affects the survival and
growth of the bacteria. Thus, future work may well reveal that the
P2X7 receptor has—sometimes quite unexpected—roles in
modulating a variety of infectious diseases, not just those that
parasitise macrophages.
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